An Australian Patent Opposition, Revocation and Extension of Term Round-Up from the Patent Office Journal dated 7 February 2013.
If you wish to oppose the grant of a patent, or if your grant own application has been opposed by third parties, please contact us.
Acceptance of the following patent applications has been opposed:
|Recombinant or transgenic factor VII composition, each factor VII molecule having two N-glycosylation sites with defined glycan units||LFB Biotechnologies||Steven Borovec|
Acceptance of the following patent applications has been opposed under section 104(4)
|2010200162||Core Sample Orientation||Australian Mud Company Pty Ltd||Coretell Pty Ltd|
Opposition to acceptance of the following applications has been withdrawn, and the application shall proceed to sealing:
|2007313700||Performing trick play functions in a digital video recorder with efficient use of resources||TiVo Inc.||Foxtel Management Pty Ltd|
|2008316558||Method and apparatus for transitioning a heavy equipment hauling rear loading trailer between transport and loading positions||Hagenbuch, L.||Bosich (1955) Pty. Ltd.|
|2005322067||Polymer-von Willebrand factor-conjugates||Baxter Healthcare SA; Baxter International Inc.||Pickering, W.|
|2006240038||Materials and methods for respiratory disease control in canines||Cornell Research Foundation, Inc.; University of Florida Research Foundation, Inc.; The Government of the United States of America As Represented by the Secretary of the Department of Health and Human Services, Centers for Disease Control and Prevention||Pickering, W.|
No additional opposition proceedings have been dismissed.
No additional applications have been withdrawn following opposition.
Extensions of Term of Standard Patents
No applications for Extension of Term under Section 70 have been made.
No additional application(s) for Extension of Term have been accepted under Section 74.
The following applications for Extension of Term have been granted under Section 76:
|Patent No.||Title||Patenee(s)||Goods||First Reg Approval Date||Extension of Term Expiry Date|
|2003240669||Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic||Novartis AG||RASILAMLO HCT aliskiren, amlodipine, hydrochlorothiazide||12 Jun 2012||Extension of Term of patent pursuant to Section 77 expires on 12 Jun 2027|
Surrendered and Revoked Letters Patent
Surrendered Letters Patent
No patents have been offered for surrender.
Revocation of Letters Patent
The following patents have been wholly or partially revoked in accordance with Section 137:
|Patent No.||Title||Patentee(s)||Date of Patent|
|2010100643||Wear plate||Bradken Resources Pty Limited||13.12.2012|